Investing

Pacira Biosciences CFO cross sells $626k in shares

Following these transactions, Cross directly owns 56,250 shares of Pacira BioSciences. In other recent news, Pacira BioSciences reported its Q3 2025 earnings, highlighting a revenue increase fueled by ...
Fox 5 San Diego

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / December 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the ...
Investing

Pacira BioSciences surges 62% since InvestingPro’s October 2024 Fair Value alert

In October 2024, InvestingPro’s Fair Value models identified Pacira BioSciences (NASDAQ:PCRX) as significantly undervalued, signaling a potential opportunity for investors. Since that alert, the stock ...
Business Insider

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of ...
Law

Pacira Pharmaceuticals, Inc. and Pacira Biosciences, Inc. v. Qilu Pharmaceutical (hainan) Co., Ltd., and Qilu Pharma, Inc.

New Suit - Patent case: Pacira Pharmaceuticals, Inc. and Pacira Biosciences, Inc. v. Qilu Pharmaceutical (hainan) Co., Ltd., and Qilu Pharma, Inc. 2:25-cv-06742 ...
Investing

Pacira’s iovera° shows better outcomes than RFA for chronic back pain

BRISBANE, Calif. - Pacira BioSciences, Inc. (NASDAQ:PCRX) announced results from a randomized 30-patient pilot study showing its iovera° cryoneurolysis treatment demonstrated better outcomes than ...
Yahoo Finance

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency ...

BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...